Policy

Reference countries have limited room to simply raise their own drug budgets to absorb the pressure, the lead study author explains.

Trial, transplant equity gaps in AML; Texas Medicaid funding dispute; pediatric GLP-1 access gaps; earlier biologic use; eye care restores vision.

NCCN survey finds universal, persistent generic drug shortages; coping tactics stretch teams as looming tariffs threaten more supply disruptions.

CMS is withholding $9.8 billion in Texas Medicaid hospital funding tied to CHIRP, costing hospitals $27 million a day in a tax dispute.

CMS awarded NY, RI, and MI Rural Health Transformation Program funding to expand rural health care workforce and technology access.

Bioethicists say Kalshi's FDA and clinical trial betting markets risk bias, insider trading, and misleading signals about drug value.

Experts discuss what SCAN Health Plan's new Medicare Advantage (MA) partnership with Costco could mean for beneficiaries, competition, and costs.

Ninety-six percent of the study population also had confirmed chronic traumatic encephalopathy on autopsy.

This extension to smaller drugmakers addresses a gap that has increasingly drawn attention from policy watchers.

DOJ policy shifts have put HHS on the same side as states seeking to narrow Section 504's disability integration mandate in Texas v Kennedy.

Experts discussed childhood vaccine recommendations, school requirements, exemptions, misinformation, and vaccine hesitancy.

A poll finds awareness of the mifepristone abortion pill is rising, but safety doubts and legal battles persist.

AHIP's Jeanette Thornton details health care's prior authorization commitments as a 2027 real-time approval target approaches.

Medicare Part D changes, premium stabilization expiration, and a Bridge demonstration converge with rising GLP-1 demand and costs.

CMS is funding 138 grants worth $144M to expand rural mental health, maternal, and emergency care access across Alabama.

FDA advisers overrode their own scientists to back 6 peptides for compounding, even as safety data remains thin and gray-market risks persist.

Based on these results, the investigators are extending their follow-up into adolescence.

Heidi Overton, MD, PhD, a physician and White House health policy aide, would replace acting commissioner Kyle Diamantas, JD.

Previous research has tied the loosening of permit-to-purchase and concealed carry laws to increased firearm suicide rates.

New hypertension drugs cost over $800,000 per QALY vs generics, well above cost-effectiveness limits, ICER's draft report finds.

Eli Lilly's investigational triple agonist is already fueling gray-market sales and a $1 trillion valuation narrative ahead of its 2027 FDA filing.

Rising premiums and out-of-pocket costs top Americans' health care concerns across party lines, a Commonwealth Fund survey finds.

Taking effect in October 2026, the final rule will end federal Medicaid and CHIP funding for gender-affirming care for transgender minors.

A new international platform trial groups rare pediatric sarcoma substudies under 1 protocol to speed drug access and data collection.

Trump's vaccine executive order calls for fewer routine childhood vaccines and changes to MMR, raising questions about coverage, access, and vaccine uptake.